UBS Group’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $205M | Buy |
2,561,776
+931,016
| +57% | +$76.8M | 0.03% | 605 |
|
|
2025
Q4 | $139M | Sell |
1,630,760
-425,175
| -21% | -$34.9M | 0.02% | 781 |
|
|
2025
Q3 | $160M | Buy |
2,055,935
+219,440
| +12% | +$17.1M | 0.03% | 708 |
|
|
2025
Q2 | $144M | Sell |
1,836,495
-423,399
| -19% | -$31.6M | 0.02% | 718 |
|
|
2025
Q1 | $164M | Sell |
2,259,894
-426,151
| -16% | -$30.5M | 0.03% | 620 |
|
|
2024
Q4 | $199M | Buy |
2,686,045
+895,890
| +50% | +$62.7M | 0.04% | 515 |
|
|
2024
Q3 | $118M | Buy |
1,790,155
+132,265
| +8% | +$9.61M | 0.03% | 642 |
|
|
2024
Q2 | $153M | Buy |
1,657,890
+235,704
| +17% | +$20.9M | 0.04% | 445 |
|
|
2024
Q1 | $136M | Buy |
1,422,186
+2,982
| +0.2% | +$250K | 0.03% | 503 |
|
|
2023
Q4 | $108M | Sell |
1,419,204
-951,132
| -40% | -$66.2M | 0.03% | 542 |
|
|
2023
Q3 | $164M | Buy |
2,370,336
+302
| +0% | +$24.3K | 0.06% | 334 |
|
|
2023
Q2 | $224M | Buy |
2,370,034
+222,623
| +10% | +$19.3M | 0.08% | 261 |
|
|
2023
Q1 | $178M | Sell |
2,147,411
-162,808
| -7% | -$12.8M | 0.06% | 284 |
|
|
2022
Q4 | $172M | Sell |
2,310,219
-58,311
| -2% | -$4.49M | 0.06% | 314 |
|
|
2022
Q3 | $196M | Sell |
2,368,530
-145,446
| -6% | -$14M | 0.09% | 241 |
|
|
2022
Q2 | $239M | Buy |
2,513,976
+15,991
| +0.6% | +$1.66M | 0.1% | 221 |
|
|
2022
Q1 | $294M | Sell |
2,497,985
-362,168
| -13% | -$40.6M | 0.1% | 213 |
|
|
2021
Q4 | $371M | Buy |
2,860,153
+249,083
| +10% | +$29.1M | 0.11% | 192 |
|
|
2021
Q3 | $296M | Sell |
2,611,070
-141,213
| -5% | -$16.1M | 0.09% | 216 |
|
|
2021
Q2 | $285M | Buy |
2,752,283
+183,669
| +7% | +$17.3M | 0.09% | 220 |
|
|
2021
Q1 | $215M | Buy |
2,568,614
+271,440
| +12% | +$22.9M | 0.07% | 278 |
|
|
2020
Q4 | $210M | Buy |
2,297,174
+269,770
| +13% | +$22.4M | 0.07% | 267 |
|
|
2020
Q3 | $162M | Buy |
2,027,404
+196,543
| +11% | +$15.3M | 0.06% | 285 |
|
|
2020
Q2 | $127M | Sell |
1,830,861
-169,806
| -8% | -$12.1M | 0.05% | 320 |
|
|
2020
Q1 | $126M | Sell |
2,000,667
-126,801
| -6% | -$9.14M | 0.06% | 290 |
|
|
2019
Q4 | $165M | Sell |
2,127,468
-276,705
| -12% | -$21.6M | 0.06% | 297 |
|
|
2019
Q3 | $176M | Sell |
2,404,173
-44,430
| -2% | -$3.12M | 0.07% | 270 |
|
|
2019
Q2 | $151M | Sell |
2,448,603
-146,772
| -6% | -$8.87M | 0.06% | 294 |
|
|
2019
Q1 | $166M | Buy |
2,595,375
+140,085
| +6% | +$7.99M | 0.07% | 259 |
|
|
2018
Q4 | $125M | Sell |
2,455,290
-40,998
| -2% | -$2.07M | 0.06% | 314 |
|
|
2018
Q3 | $145M | Buy |
2,496,288
+61,797
| +3% | +$3.02M | 0.06% | 299 |
|
|
2018
Q2 | $118M | Buy |
2,434,491
+110,346
| +5% | +$5.15M | 0.05% | 346 |
|
|
2018
Q1 | $108M | Sell |
2,324,145
-251,961
| -10% | -$10.9M | 0.05% | 364 |
|
|
2017
Q4 | $96.8M | Buy |
2,576,106
+15,156
| +0.6% | +$556K | 0.04% | 420 |
|
|
2017
Q3 | $93.3M | Sell |
2,560,950
-174,333
| -6% | -$6.65M | 0.04% | 391 |
|
|
2017
Q2 | $108M | Buy |
2,735,283
+114,204
| +4% | +$4.17M | 0.06% | 348 |
|
|
2017
Q1 | $82.2M | Buy |
2,621,079
+428,577
| +20% | +$13.4M | 0.04% | 390 |
|
|
2016
Q4 | $68.5M | Buy |
2,192,502
+357,243
| +19% | +$11.6M | 0.04% | 429 |
|
|
2016
Q3 | $73.8M | Buy |
1,835,259
+132,855
| +8% | +$5M | 0.04% | 406 |
|
|
2016
Q2 | $56.6M | Buy |
1,702,404
+431,271
| +34% | +$14.8M | 0.04% | 456 |
|
|
2016
Q1 | $37.4M | Sell |
1,271,133
-35,271
| -3% | -$973K | 0.03% | 577 |
|
|
2015
Q4 | $34.4M | Buy |
1,306,404
+455,562
| +54% | +$11.8M | 0.02% | 664 |
|
|
2015
Q3 | $20.2M | Buy |
850,842
+63,840
| +8% | +$1.54M | 0.01% | 884 |
|
|
2015
Q2 | $18.7M | Sell |
787,002
-84,756
| -10% | -$1.91M | 0.01% | 1025 |
|
|
2015
Q1 | $20.7M | Sell |
871,758
-14,556
| -2% | -$327K | 0.01% | 940 |
|
|
2014
Q4 | $18.8M | Buy |
+886,314
| New | +$17.8M | 0.01% | 1030 |
|
Other funds holding EW
VCM
VPM
UBS Group's EW Position: Q1 2026 in Review
UBS Group increased its Edwards Lifesciences (EW) stake by 57% in Q1 2026, buying an estimated $76.8M and bringing the position to 2,561,776 shares worth $205M. The position accounts for 0.03% of the portfolio, ranked #605.
UBS Group first reported a position in EW in Q4 2014 and has held it in 46 quarters since. The position peaked at $371M in Q4 2021. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- UBS Group held 2,561,776 shares of Edwards Lifesciences worth $205M as of Q1 2026.
- UBS Group bought 931,016 Edwards Lifesciences shares in Q1 2026, an estimated $76.8M.
- Edwards Lifesciences made up 0.03% of UBS Group's portfolio in Q1 2026, its #605 holding.
- UBS Group first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Edwards Lifesciences position peaked at $371M in Q4 2021.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.